Feedback / Questions
EGFRvIII CAR - National Cancer Institute, Gilead
Kite Pharma: Corporate Presentation
(Kite Pharma)
-
May 22, 2015 -
Anticipdated data from P1/2 trial (NCT01454596) for glioblastoma in 2016
Anticipated P1/2 data
•
Oncology
http://files.shareholder.com/downloads/AMDA-2V2XOY/206805876x0x826437/44464B98-6357-4F7A-85A1-B9C164989D16/May_Presentation_-_FINAL.pdf
May 22, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.